Navigation Links
CIBC World Markets Equity Research Downgrades Target Price of BVF from $12.00 to a Staggering Low of $7.50 Based on Potential Incumbent Win in Proxy Battle
Date:6/20/2008

Not too late to Protect Your Investment and Vote for A Better Biovail

TORONTO, June 20 /PRNewswire/ - The Concerned Shareholders remind fellow shareholders of Biovail that it is not too late to vote your YELLOW proxy for a Better Biovail. It is more than clear that change is needed. Industry experts, CIBC World Markets - Equity Research, have today changed their recommendation for BVF to sector underperformer based on the proposed strategy of the Company going forward proposed by the Incumbent Board and management team.

According to CIBC, the reasons for this downgrade include:

(x) "Biovail's poor growth prospects, limited pipeline visibility and our

expectation for a long restructuring lead us to believe that Biovail

will underperform its peers going forward.

(x) In addition, we believe that Biovail's dividend policy is not

sustainable. We forecast declining cash flows and hold the view that

the company will need to use its cash to support distributions in the

near term. We would rather see the company preserve its capital for

eventual acquisitions.

(x) We also have modest expectations as it relates to Biovail's new focus

on Central Nervous System (CNS) disorders, as we view the clinical

development risks as relatively high and the existing market as

highly competitive. The CNS market is also highly genericized."

Furthermore, the report goes on to state that, "we believe the likelihood of a reduction or elimination of the dividend is quite high." CIBC wonders how "the company's current product portfolio will generate sufficient cash flows to support the payments given our impression that some of the company's products may be facing generic competition in the near term." Finally CIBC "fails to see how paying ~$240 million/year in dividends makes sense given the company's new strategy."

The Concerned Shareholders urge all shareholders to read the CIBC report in its entirety and agree with CIBC's analysis. The Concerned Shareholders fully align with CIBC's analysis that should the Incumbent Board and management win the proxy battle the price for BVF will dramatically fall. The status quo at Biovail is simply not acceptable. It is time to protect your investment and vote for change at Biovail.

It is not too late to cast your YELLOW proxy and support a forward thinking and innovative plan that relies on the leadership of independent, trusted and successful pharmaceutical sector entrepreneurs with a plan to evolve with the rate of change in the industry.

Even if you have already voted in favour of management, you may change your vote by completing and submitting a YELLOW proxy dated later than the previously submitted proxy.

For further information on how to vote your YELLOW proxy please visit http://www.betterbiovail.com and click on 'vote now'.


'/>"/>
SOURCE A Better Biovail
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. World Vision Responding to Record Flooding in Midwest
2. Worldwide War Deaths Underestimated
3. Agendia Expands Laboratory Capacity at New Amsterdam Headquarters to Meet Increasing Demand for Services Worldwide
4. World research leaders gather in Finland to accelerate the development of bioactive paper
5. 10th World Congress on Gastrointestinal Cancer -- Barcelona, Spain
6. World Renowned Hand Surgeon Helps Patients Conquer Joint Discomfort Naturally
7. Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
8. PartsSource Given 2008 World Class Customer Service Award for Second Straight Year
9. WORLDFOODS Provides All Natural Authentic Asian Sauces That Cater to Vegetarians, Celiacs and Those With Food Allergies
10. Essilor Agrees to Acquire Satisloh The World Leader in Optical Manufacturing Solutions
11. Rotary Brings the World to Los Angeles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance ... assistance to clients in southern Montana, is announcing a focused charity effort to ... The outreach programs offered by Zoo Montana provide students with current knowledge on ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... ... 27, 2017 , ... Excel Medical, the leader in Next-Generation ... of Executive Vice President, Sales and Marketing. Finnegan is a widely known industry ... sales leadership. He has received industry recognition for innovations and new approaches to ...
(Date:6/27/2017)... PA and London UK (PRWEB) , ... June 27, 2017 , ... ... applying to a clinical study is whether they can trust the sponsor to pay ... it is vital that sponsors and CROs establish payment strategies that encourage sites to ...
(Date:6/27/2017)... ... 27, 2017 , ... Salucro, the cloud-based payment platform that ... hospitals and provider groups, has announced that it will now offer Parasail’s payment ... a San Francisco health-finance startup that has launched a series of tech-based products ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)...  Eli Lilly and Company (NYSE: ... Phase 3 MONARCH 2 study showed that abemaciclib, ... combination with fulvestrant, significantly improved progression-free survival (PFS) ... with hormone-receptor-positive (HR+), human epidermal growth factor receptor ... or progressed after endocrine therapy (median PFS, 16.4 ...
(Date:5/30/2017)... May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... today announced that it will be presenting at the 7th annual ... PT. Erez Raphael , CEO, of DarioHealth will be giving ... be held on June 6th & 7th, 2017 at the Luxe ... small / micro-cap space. About ...
(Date:5/29/2017)... 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... enables the functional selection of stem cells, today provided ... first quarter ended March 31 st , 2017. ... in the first quarter of 2017," said Dr. Shai ... announced the treatment of the first blood cancer patient ...
Breaking Medicine Technology: